

Behind The Most Exciting Stock Pop In Years!
Target reported solid earnings this morning, which is a great sign for the consumer, but the big news today was from Moderna. The company’s clinical trial results for a cancer vaccine were so encouraging it was fast tracked through the trial and, while there are questions, this could change how we look at cancer in…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Motley Fool Hidden Gems Investing →
Moderna's Cancer Vaccine Breakthrough & Why Uber Could Win the Robotaxi War

AI Stocks Selloff 2026: Overreaction or a Real Warning Sign for Investors?

Nvidia’s Record Setting Run… And Trump’s Powell Pressure Ramps Up 7/15/25

The Cancer Vaccine That Could Save Moderna
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.


